Table 3.
Clinical and vaccination data from IPD patients, <5 years of age in NSW, from whom IPD serogroup 19 isolates were isolated.
| Demographic & core clinical data | 2004 | 2008 | 2014 | |
|---|---|---|---|---|
| Total cases | n = 41 | n = 60 | n = 23 | |
| Median age, years (range) | 1.45 (0.04–4.94)a | 1.76 (0.0–4.73) | 1.9 (0.0–5) | |
| Specimen type | Bloodb | 40 (98%) | 59 (98%) | 21 (91.3%) |
| Joint fluid | 1(2%) | 1 (2%) | — | |
| CSF | — | — | 2 (8.7%) | |
| Clinical presentation | Bacteremia | 22 (54%) | 31 (51.5%) | 11 (47.8) |
| Pneumonia | 11 (27%) | 25 (41.5%) | 9 (39.1) | |
| Septic arthritis | 1 (2%) | 1 (2%) | — | |
| Meningitis | — | — | 2 (8.7) | |
| Unknown | 7 (17%) | 3 (5%) | 1 (4.3) | |
| Vaccination History | Full | 1 (2%) | 50 (82%) | 15 (65%) |
| Partial | 2 (5%) | 6 (10%) | 5 (22%) | |
| None | 31 (76%) | 1 (2%) | 2 (9%) | |
| Unknown | 7 (17%) | 2 (3%) | 1 (4%) | |
| PCV-7 history | 3 doses | 1 (2.4%) | 50 (83%) | 5 (23%) |
| 2 doses | — | 6 (10%) | 1 (4%) | |
| 1 dose | 1 (2.4%) | 1 (2%) | — | |
| No PCV-7 | 29 (70.8%) | 2 (3%) | 16 (70%) | |
| Unknown | 9 (22%) | 1 (2%) | 1 (4%) | |
| PCV-13 history | 3 doses | — | — | 10 (44%) |
| 2 doses | — | — | 4 (17%) | |
| 1 dose | — | — | 1 (4%) | |
| No PCV13 | — | — | 7 (30%) | |
| Unknown | 1 (4%) | |||
| PPV-23 history | 1 dose | 1 (2.4%) | — | — |
| Immune status | Compromised | 3 (7%) | 1 (2%) | 2 (9%) |
| Competent | 32 (78%) | 59 (98%) | 20 (87%) | |
| Unknown | 6 (15%) | — | 1 (4%) | |
| Indigenous statusc | Non-indigenous | 98% | 95% | 21 (91%) |
| Indigenous | 2% | 5% | 2 (9%) |
Notes:
aAge unknown for 3 IPD cases in 2004.
bClinical presentation of bacteremia includes an unknown number of cases of meningitis (lumbar puncture often performed after antibiotic therapy commenced).
cAggregated percentage of IPD cases in Indigenous and non-indigenous populations where included in study years 2004 and 2008. In 2014, notified cases of IPD in Indigenous.
dAbbreviations: PCV-7; −13-7 or 13-valent pneumococcal conjugate vaccine; PPV-23-23-valent pneumococcal polysaccharide vaccine. and non-indigenous children is reported.